companiesCompany

Bristol Myers Squibb

aka Bristol-Myers Squibb, Juno Therapeutics, Mirati Therapeutics, Celgene, American Regent, Inc., American Regent, YM BioSciences

Pioneer of checkpoint inhibitors (Opdivo, Yervoy), now betting on the first successful bispecific ADC and alpha radiopharmaceuticals.

Bristol Myers Squibb, based in Princeton and listed as BMY, is the pioneer of checkpoint inhibitors with Opdivo and Yervoy, and it is now betting on the first successful bispecific antibody-drug conjugate and on alpha radiopharmaceuticals. Its portfolio spans nivolumab, ipilimumab and Opdualag, adagrasib from Mirati, the CAR-T products Breyanzi and Abecma, izalontamab brengitecan licensed from SystImmune for 8.4 billion dollars, actinium-225 DOTATATE from the 4.1 billion dollar RayzeBio purchase, and a PD-L1 by VEGF bispecific licensed from BioNTech for 11 billion dollars in 2025. Nuclide links it to the ten-year CheckMate 067 follow-up, CheckMate 649 and CheckMate 816 papers, to luspatercept, and to KRAS inhibitors and protein degradation. Whether its large bets on ADCs and radiopharmaceuticals pay off as the nivolumab franchise ages is the open question.

Headquarters

Princeton, NJ, US

Scorecard

All companies

#36of 90 companies, score 9

phase 3 +3
targets +2
modalities +2
registry trials +2

0 approved, 1 in phase 3, 0 earlier, 1 targets, 1 registry studies. Formula on the about page.

Financial snapshot, FY2024

Total revenue: $48.3bn
R&D spend: $11.2bn
Cash: $10.3bn

Opdivo $9.3bnRevlimid $5.8bnPomalyst $3.5bn

Cash is cash and cash equivalents only. Revlimid and Pomalyst are in generic erosion. Bristol Myers Squibb Form 10-K, FY2024 (SEC EDGAR)

Deals

Deal map

Date	Deal	Type	Upfront	Total	Source
2023-12-26	RayzeBio (BMS) to Bristol Myers Squibb RYZ101 (actinium-225 DOTATATE) and an actinium-based radiopharmaceutical platform	Acquisition	$62.50 per share in cash	about $4.1bn equity value, $3.6bn net of estimated cash acquired	source

Manufacturing

Capacity map

Bristol Myers Squibb Devens Devens, Massachusetts, US
Cell therapy, Antibody drug substance
Cellares Smart Factory South San Francisco, California, US · Cellares
Cell therapy

Type

pharma · BMY

Stage

Public

Website

www.bms.com